Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells
- 570 Downloads
Treatment strategies for medication-related osteonecrosis of the jaw (MRONJ) remain controversial. Although the AAOMS suggests a conservative approach, a surgical management with necrosectomy is often required when conservative management has failed. Moreover, recent studies have shown promising results using an early stage surgical treatment. Over the past decade, cell-based bone regeneration utilizing bone marrow mesenchymal stem cells (MSCs) received increased attention. MSCs are known to promote wound healing and induce new bone formation in compromised tissue. Accordingly, the aim of this study was to assess the role of MSCs in the management of MRONJ. This study included 6 patients referred to our department with the diagnosis of MRONJ. Upon informed consent, the patients underwent surgical resection of necrotic bone followed by MSCs grafting. The MSCs were separated from bone marrow cells aspirated from the iliac crest using a bone marrow aspirate concentrate system. The MSCs were grafted into the defect with autologous thrombin and the defect was covered with a collagen membrane. In all cases, bony edges were rounded and the wound was closed using a three-layered technique. In the follow-up from 12 to 54 months, all patients including those who had impaired conditions, sepsis, or pathological fracture, showed satisfactory healing with no signs of wound infection. This pilot study indicated that surgical management in combination with MSCs transplantation seems to be a promising treatment modality in the therapy of MRONJ.
KeywordsMedication-related osteonecrosis of the jaw Bisphosphonate Mesenchymal stem cells Stem cell transplantation
This study was supported by the Osteology Foundation Grant No. 08-026.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the local Ethics Committee of the University of Freiburg (Nr. 242/09).
All patients signed informed consent before involvement into the study.
- 3.Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2014;72(10):1938–56.CrossRefGoogle Scholar
- 6.Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Min Res Off J Am Soc Bone Min Res. 2008;23(6):826–36.CrossRefGoogle Scholar
- 8.Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2010;18(4):449–60.Google Scholar
- 9.Voss PJ, Joshi Oshero J, Kovalova-Muller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, Lemound J, Metzger MC, Schmelzeisen R. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Cranio Maxillo Facial Surg Off Publ Eur Assoc Cranio Maxillo Facial Surg. 2012;40(8):719–25.CrossRefGoogle Scholar
- 11.Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O, Cardoso CL, dos Santos MO. Bisphosphonate-related osteonecrosis of the jaws–an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2011;69(9):2465–72.CrossRefGoogle Scholar
- 14.Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, Kuroshima S, Kawakami A, Asahina I. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg. 2015;44(12):1558–64.CrossRefPubMedGoogle Scholar
- 19.Ueda M, Yamada Y, Ozawa R, Okazaki Y. Clinical case reports of injectable tissue-engineered bone for alveolar augmentation with simultaneous implant placement. Int J Periodontics Restor Dent. 2005;25(2):129–37.Google Scholar
- 25.Gutwald R, Haberstroh J, Kuschnierz J, Kister C, Lysek DA, Maglione M, Xavier SP, Oshima T, Schmelzeisen R, Sauerbier S. Mesenchymal stem cells and inorganic bovine bone mineral in sinus augmentation: comparison with augmentation by autologous bone in adult sheep. Br J Oral Maxillofac Surg. 2010;48(4):285–90.CrossRefPubMedGoogle Scholar
- 27.Duttenhoefer F, Hieber SF, Stricker A, Schmelzeisen R, Gutwald R, Sauerbier S. Follow-up of implant survival comparing ficoll and bone marrow aspirate concentrate methods for hard tissue regeneration with mesenchymal stem cells in humans. BioRes Open Access. 2014;3(2):75–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Sauerbier S, Stricker A, Kuschnierz J, Buhler F, Oshima T, Xavier SP, Schmelzeisen R, Gutwald R. In vivo comparison of hard tissue regeneration with human mesenchymal stem cells processed with either the FICOLL method or the BMAC method. Tissue Eng C Methods. 2010;16(2):215–23.CrossRefGoogle Scholar
- 29.Elda S, Czerninski R, Avgil M, Or R. Hematopoietic stem cells local transplantation for the treatment of osteonecrosis of the jaws. Support Care Cancer. 2005;13:455.Google Scholar
- 37.Mast G, Otto S, Mucke T, Schreyer C, Bissinger O, Kolk A, Wolff KD, Ehrenfeld M, Sturzenbaum SR, Pautke C. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Cranio Maxillo Facial Surg Off Publ Eur Assoc Cranio Maxillo Facial Surg. 2012;40(7):568–71.CrossRefGoogle Scholar
- 39.Fleisher KE, Doty S, Kottal S, Phelan J, Norman RG, Glickman RS. Tetracycline-guided debridement and cone beam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: a technical note. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2008;66(12):2646–53.CrossRefGoogle Scholar
- 43.Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Min Metab. 2010;28(4):365–83.CrossRefGoogle Scholar
- 46.Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Cranio Maxillo Facial Surg Off Publ Eur Assoc Cranio Maxillo Facial Surg. 2015;43(6):847–54.CrossRefGoogle Scholar
- 47.Wilde F, Hendricks J, Riese C, Pausch NC, Schramm A, Heufelder M. Bone regeneration without bone grafting after resection of a segment of the mandible to treat bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2011;69(10):2657–62.CrossRefGoogle Scholar